Cooperative Agreement R43TR001286

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, seeks to develop and characterize a point-of-care testing platform to enable rapid, bedside, or at-home measurement of tacrolimus, a critical immunosuppressive drug used in organ transplantation. The $306,299 award to Simplusdx, Inc. will fund the adaptation of the D4 immunoassay platform for the detection of tacrolimus, which could improve short- and long-term outcomes for transplant...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), aims to develop recombinant human enzyme panels representing genetic variants in drug-metabolizing enzymes that are present in the U.S. patient population. The $285,444 award to Precision Quantomics, Inc. will leverage recombinant proteins to create commercially viable kits for polymorphic drug-metabolizing enzymes that exhibit variability....

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), is funding the development of a high-throughput kinetic system for small-molecule drug discovery. The $329,272 award to Capienda Biotech, LLC will be used to upgrade an existing prototype instrument to enable rapid characterization of small-molecule compounds that target human cyclin-dependent kinases, which are important therapeutic targets for...

This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...

The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...

This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health federal grant program (CFDA 93.113) provides $306,872 to Bioprinting Laboratories Inc. to establish a high-throughput screening platform using genetically engineered induced pluripotent stem cells (iPSCs) and brain organoids to assess the developmental neurotoxicity (DNT) potential of chemicals. The key products and services to be delivered include: Development of an...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is supporting the development of novel minimally invasive catheter-based devices to capture and remove chemotherapy drugs from the blood during locoregional infusion therapy. The goal is to reduce systemic toxicity by eliminating the target drugs from the bloodstream...

The National Center for Advancing Translational Sciences (NCATS) awarded a $1,050,276 Project Grant to Syntr Health Technologies, Inc. on September 25, 2025. The funding supports the development of an automated tissue processing platform called the SYNTRFUGE system and SYNTRFPU360, which is designed to dissociate solid tumor tissues into single cells for diagnostic analysis and research. This FDA-cleared technology can process various tissue types, including cancer tumors and adipose tissue,...